Related Experiment Video
Updated: Sep 1, 2025
DIPLOMA Approach for Standardized Pathology Assessment of Distal Pancreatectomy Specimens
Published on: February 1, 2020
MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases
Juliana Pereira Lopes Gonçalves1, Christine Bollwein1, Anna Melissa Schlitter1,2
1Institute of Pathology, School of Medicine, Technical University of Munich, Trogerstraße 18, 81675 Munich, Germany.
Abstract:
Cancer-related deaths are very commonly attributed to complications from metastases to neighboring as well as distant organs. Dissociate response in the treatment of pancreatic adenocarcinoma is one of the main causes of low treatment success and low survival rates. This behavior could not be explained by transcriptomics or genomics; however, differences in the composition at the protein level could be observed. We have characterized the proteomic composition of primary pancreatic adenocarcinoma and distant metastasis directly in human tissue samples, utilizing mass spectrometry imaging. The mass spectrometry data was used to train and validate machine learning models that could distinguish both tissue entities with an accuracy above 90%. Model validation on samples from another collection yielded a correct classification of both entities. Tentative identification of the discriminative molecular features showed that collagen fragments (COL1A1, COL1A2, and COL3A1) play a fundamental role in tumor development. From the analysis of the receiver operating characteristic, we could further advance some potential targets, such as histone and histone variations, that could provide a better understanding of tumor development, and consequently, more effective treatments.
Insights
This study reveals distinct protein differences between primary pancreatic cancer and its metastases using mass spectrometry imaging. These findings, including collagen fragments, could lead to better diagnostic tools and more effective pancreatic cancer treatments.
Area of Science:
- Oncology
- Proteomics
- Biochemistry
Background:
- Metastasis is a primary cause of cancer-related deaths, particularly in pancreatic adenocarcinoma, leading to poor treatment outcomes.
- Transcriptomic and genomic analyses have failed to fully explain the treatment resistance observed in pancreatic adenocarcinoma.
- Protein-level differences between primary tumors and metastases suggest a potential avenue for investigation.
Purpose of the Study:
- To characterize the proteomic composition of primary pancreatic adenocarcinoma and distant metastases.
- To identify molecular features that distinguish these tissue types.
- To explore potential therapeutic targets for improved pancreatic cancer treatment.
Main Methods:
- Mass spectrometry imaging was employed to analyze the proteomic profiles of human tissue samples from primary pancreatic adenocarcinoma and metastases.
- Machine learning models were trained and validated using the proteomic data to classify tissue entities.
- Receiver operating characteristic analysis was used to identify discriminative molecular features and potential therapeutic targets.
Main Results:
- Proteomic analysis successfully distinguished between primary pancreatic adenocarcinoma and distant metastases with over 90% accuracy.
- Validation on an independent sample set confirmed the model's classification accuracy.
- Collagen fragments (COL1A1, COL1A2, COL3A1) were identified as key discriminative features involved in tumor development.
- Histone variations were highlighted as potential targets for further investigation.
Conclusions:
- Proteomic profiling via mass spectrometry imaging offers a powerful approach to differentiate primary pancreatic tumors from metastases.
- Collagen fragments and histone variations represent promising biomarkers and therapeutic targets for pancreatic cancer.
- Understanding these protein-level distinctions can pave the way for more effective treatment strategies and improved patient survival rates.
